+ Watch SGEN
on My Watchlist
A biotechnology company, which develops monoclonal antibody-based therapies for the treatment of cancer and autoimmune diseases.
$2.34B for a drug which treats HL and ALCL seems very, very rich, even when taking SGEN's strong balance sheet into account. Very cool platform, but the target for brentuximab vedotin is expressed on a narrow enough set of tumor types to keep this drug as a commercially modest proof of concept for the platform. Hats off to SGEN, which has maximized value for this asset, they've done a great job of hyping its potential and swindled Takeda out of a $60M upfront payment for ex-US rights. Hard to see this drug breaking $250M peak in the US even with very aggressive pricing, which makes the $2.34B market cap look very shaky.
Adcetris was approved yesterday. Now things will get interesting, as it becomes much easier to calculate realistic revenues from that drug, and then build a much cleaner valuation of the company than you could previously. A lot of stocks have gone down recently following approval (HGSI, OPTR), so it'll be interesting to see what happens with SGEN. If you assume $20k-ish/month the current valuation is still far too high, even assuming strong penetration into the target population. Trials are ongoing for earlier stage use, but in a tumor type with 80%+ cure rates it's going to be a lot harder to make the case for use there than in relapsed/refractory patients. I'm maintaining my thumbs down, despite enthusiasm over the approval.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions